Indexat a

Enllaç extern

Llicència i ús

Citacions

Altmetrics

Anàlisi d'autories institucional

Pernas, SAutor o coautorPomares, HAutor o coautorAsiaín, LAutor o coautorNadal, EAutor o coautor

Compartir

Pericardial Disease in Patients with Cancer: Clinical Insights on Diagnosis and Treatment

Publicat a:Cancers. 16 (20): 3466- - 2024-10-01 16(20), DOI: 10.3390/cancers16203466

Autors: Lorenzo-Esteller, L; Ramos-Polo, R; Riverola, AP; Morillas, H; Berdejo, J; Pernas, S; Pomares, H; Asiain, L; Garay, A; Pérez, EM; Jiménez-Marrero, S; Alcoberro, L; Nadal, E; Gubern-Prieto, P; Gual-Capllonch, F; Hidalgo, E; Enjuanes, C; Comin-Colet, J; Moliner, P

Afiliacions

Resum

Simple Summary Pericardial disease is a common and severe complication in patients with cancer, often presenting as acute pericarditis, pericardial effusion, or constrictive pericarditis. Causes include direct tumor invasion, metastasis, and cancer treatments like chemotherapy and radiotherapy. Lung cancer is the most frequent etiology, followed by breast cancer and lymphomas. Early detection and multidisciplinary management are crucial. Acute pericarditis requires careful diagnosis and treatment with NSAIDs and colchicine. Pericardial effusion is commonly incidental but can lead to cardiac tamponade, necessitating pericardiocentesis or a pericardial window. Immunotherapy-related effusions typically respond to treatment cessation and steroids. Constrictive pericarditis, although rare, requires prompt diagnosis and may necessitate surgical intervention. Multidisciplinary care and early intervention are vital for improving patient outcomes and quality of life.Abstract Pericardial disease is increasingly recognized in cancer patients, including acute pericarditis, pericardial effusion, and constrictive pericarditis, often indicating a poor prognosis. Acute pericarditis arises from direct tumor involvement, cancer therapies, and radiotherapy. Immune checkpoint inhibitor (ICI)-related pericarditis, though rare, entails significant mortality risk. Treatment includes NSAIDs, colchicine, and corticosteroids or anti-IL1 drugs in refractory cases. Pericardial effusion is the most frequent manifestation, primarily caused by lung cancer, followed by breast cancer, lymphoma, leukemia, gastrointestinal tumors, and melanoma. Chemotherapy, immunotherapy, and radiotherapy may also cause fluid accumulation in the pericardial space. Symptomatic relief for pericardial effusion may require pericardiocentesis, prolonged catheter drainage, or a pericardial window. Instillation of intrapericardial cytostatic agents may reduce recurrence. Constrictive pericarditis, though less common, often develops from radiotherapy and requires multimodality imaging for diagnosis, with pericardiectomy as the definitive treatment. Primary pericardial tumors are rare, with metastases being more frequent. Patients with cancer and pericardial disease generally have poor survival, emphasizing the need for early detection. A multidisciplinary approach involving hematologists, oncologists, and cardiologists is crucial to tailoring pericardial disease treatment to a patient's clinical status, thereby improving the quality of life and prognosis.

Paraules clau